Marked against last year's 10-K:
cut words struck through, new words highlighted and underlined.
Legal Proceedings New paragraph this year (276 words), with no similar paragraph last year.
On April 24, 2025, the United States District Court for the District of Massachusetts entered final judgment in favor of Insulet Corporation in its ongoing litigation against EOFlow Co., Ltd.; EOFlow, Inc.; Nephria Bio, Inc.; and EOFlow’s CEO, Jesse Kim (collectively, “Defendants”), Insulet Corp. v. EOFlow Co. Ltd. et al., 1:23-cv-11780-FDS (D. Mass.). The litigation concerned the Defendants’ misappropriation of Insulet’s proprietary trade secrets relating to the design and manufacture of the Omnipod insulin patch pump. On December 3, 2024, a unanimous jury found four trade secrets asserted by Insulet valid and misappropriated and awarded Insulet total damages of $452 million, composed of $170 million in compensatory damages and $282 million in exemplary damages. The district court’s April 24, 2025 orders upheld the jury verdict and further entered a permanent injunction against Defendants. The injunction prohibits Defendants and others subject to the order from using, possessing, selling, distributing, or seeking regulatory approval for any products that were designed, developed, or manufactured, in whole or in part, using or relying on Insulet’s trade secrets. The injunction is worldwide and took effect immediately subject to a limited exception that permits six months of continuing sales to those patients of EOFlow that existed in the Republic of Korea and the European Union as of October 2023. The permanent injunction further requires EOFlow to assign certain patent applications to Insulet, disgorge any break-up fees received from Medtronic in connection with a previously contemplated acquisition, and submit to ongoing audits to ensure compliance with the district court’s orders. In view of the scope of the permanent injunction, the Court reduced Insulet’s monetary award to $59.4 million to avoid a double recovery.
Source: Item 3, via Note 16 – Commitments and Contingencies, 10-K 0001145197-26-000028 vs Item 3, via Note 18 – Commitments and Contingencies, 10-K 0001145197-25-000007
MD&A 260 words changed in this paragraph; it is 40% similar to last year's version.
We exercise significant judgment generally recognize revenue when control of our products is transferred to customers in an amount that reflects the net consideration we determine variable consideration adjustments. As discussed in Note 2 expect to our consolidated financial statements, we receive. Our products are subject to pricing rebates on pricing programs under arrangements with managed care organizations, such as including pharmacy benefit managers, governmental payors, and third-party commercial payors, primarily in the United States. Reductions These rebates represent amounts owed pursuant to our revenues contractual agreements or legal requirements after the product is dispensed to a benefit plan participant. Provisions for rebates on products sold through our distributors under these rebates, collectively referred to as pharmacy benefits rebates, are treated as variable consideration and are recorded as a reduction to revenue using the most significant component of variable consideration. In addition, pharmacy rebates are most expected value method. Although we record a rebate provision at risk for significant adjustment because of the time delay between of sale, the recording of the provision when revenue is recognized and its ultimate settlement, an interval that related rebate payments are generally ranges from made 30 to 90 days, but can last days thereafter and, in certain cases, may extend up to one year. Our estimates for As a result of this timing difference, revenue recognized in a given period may include adjustments to rebate provisions recorded in prior periods. Estimates of pharmacy rebates are developed based on historical experience, revenue growth, sales trends, levels of inventory in the distribution channel lag, contract amendments channel, and trends. Pharmacy rebates contractual terms. A significant portion of our rebate provisions relate to sales of the Company’s products in the United States. United States pharmacy rebate provisions charged against gross sales amounted to $654.7 million, $452.7 million, and $367.3 million, and $175.2 million in 2025, 2024, and 2023, and 2022, respectively. When To the extent that actual pharmacy rebate settlements payments differ from our estimates, we adjust revise our estimates, which affects reported assumptions and record the resulting adjustments to revenue in the period that in which such variances differences become known.
Source: Item 7, 10-K 0001145197-26-000028 vs Item 7, 10-K 0001145197-25-000007
Risk Factors 217 words changed in this paragraph; it is 55% similar to last year's version.
As we continue to expand the number of customers we serve, driven in large part by significant increasing demand for Omnipod 5, our international expansion and entrance into the insulin-requiring type 2 diabetes market, we expect to continue to increase our manufacturing capacity, our personnel, and the scope of our sales and marketing efforts. This growth, as well as any other Our growth that we may experience in the future, will create challenges for our organization and may strain our management and operations resources, including our customer service. In order to manage future growth, we will be required to improve existing, and implement new, sales and marketing efforts, distribution channels, management, operations, and customer support procedures. In addition, the form and function of our enterprise information technology systems will need to change and be improved upon as our business needs change. For example, we recently implemented a new enterprise resource planning system and plan to upgrade our customer relationship management system. We will also need to manage our supply chain and manufacturing effectively, including our sourcing of materials such as semiconductor chips. We may also need to partner with additional third-party suppliers to manufacture certain components of our Omnipod products and install additional manufacturing lines, including as a part of our newly constructed facility in Malaysia. A transition to new suppliers may result in additional costs or delays. service resources. We may misjudge the amount of time or resources that will be required to effectively manage any anticipated or unanticipated growth in our business, or we may not be able to manufacture sufficient inventory, or and we may not be able to attract, hire, and retain sufficient personnel to meet our expanding needs. If we cannot scale our business appropriately, maintain control over expenses, manufacture our products in a cost-effective or timely manner, or otherwise adapt to anticipated and unanticipated growth, our business resources may become strained, customer experience may decline, and we may not be able to deliver our Omnipod products in a timely manner, and all of which would adversely affect our results of operations may be adversely affected. operations.
Source: Item 1A, 10-K 0001145197-26-000028 vs Item 1A, 10-K 0001145197-25-000007
Accounting Policies 101 words changed in this paragraph; it is 61% similar to last year's version.
The Company’s Drug Delivery product line includes sales of a modified version of the Pod to a pharmaceutical and biotechnology companies company who use the Company’s technology as a delivery method for their drugs. For the majority of this product line, revenue is recognized, with an associated unbilled receivable, as the The product is produced pursuant to the customer’s firm purchase commitments. The commitments, the Company has an enforceable right to payment for performance completed to date date, and the inventory has no alternative use to the Company. The Company recognizes Accordingly, revenue is recognized over time using a blend of percentage-of-completion method, measured based on costs incurred to date relative to total estimated costs at completion and time incurred to date relative to total production time to measure progress toward completion, which results in the satisfaction recognition of its performance obligations. The Company believes that both incurred cost and elapsed time reflect the value generated, which best depicts the transfer of control to the customer. Contract costs include third-party costs as well as an allocation of manufacturing overhead. associated unbilled receivable.
Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001145197-26-000028 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001145197-25-000007
